Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively.
Reference
1. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Cell. 89:309-19
2. Schoppet M, Preissner KT, Hofbauer LC. 2002. Arterioscler Thromb Vasc Biol. 22:549-53
3. Tsuda E, Goto M, Mochizuki S, et al. 1997. Biochem Biophys Res Commun. 234:137-42
4. Luan X, Lu Q, Jiang Y, et al. 2012. J Immunol. 189:245-52.